E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Considering the high percentage of grade 1 and 2 perineal lacerations, it is evident that another route of administration of the anaesthetic could be of great help in further reducing the discomfort of the woman. In particular, the use of topical lidocaine spray administered by nebulisation onto the wound could ensure greater clinical efficacy on pain control, pain-free administration, and ease of use by operators. |
Considerando l’alta percentuale di lacerazioni perineali di grado 1 e 2 risulta evidente come potrebbe essere di grande ausilio l’utilizzo di un’altra via di somministrazione dell’anestetico al fine di ridurre ulteriormente il discomfort della donna. L’utilizzo della lidocaina spray per uso topico somministrata attraverso nebulizzazione sulla ferita potrebbe garantire una maggiore efficacia clinica sul controllo del dolore ed una maggiore facilità d’utilizzo da parte degli operatori. |
|
E.1.1.1 | Medical condition in easily understood language |
To evaluate the efficacy and safety of using a spray anaesthetic during suturing of perineal lacerations, comparing it with the standard technique. |
Valutare l’efficacia e la sicurezza dell’utilizzo di un anestetico spray durante la sutura di lacerazioni perineali, confrontandola con la tecnica standard. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10021428 |
E.1.2 | Term | Immune system disorders |
E.1.2 | System Organ Class | 10021428 - Immune system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the effectiveness of treating pain during suturing of postpartum perineal lacerations with lidocaine spray vs skin infiltration. |
Confrontare l’efficacia del trattamento del dolore durante la sutura delle lacerazioni perineali post-partum con nebulizzazione di lidocaina spray vs infiltrazione cutanea. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Grade I or II post-partum perineal laceration requiring suturing; - full-term delivery (beyond 36 weeks and 6 days of gestation) - over 18 years of age - childbirth at the top; - understanding of the Italian language; - consent to participate in the study. |
• lacerazione perineale post-partum di I o II grado con necessità di sutura; • parto a termine (oltre le 36 settimane e 6 giorni di gestazione • età superiore a 18 anni; • parto di vertice; • comprensione della lingua italiana; • consenso a partecipare allo studio. |
|
E.4 | Principal exclusion criteria |
- epidural anaesthesia during the 2 hours preceding delivery; - operative delivery with the application of forceps or suction cups; - psychiatric pathology; - twin births; - known allergies to study instruments - previous adverse reactions to local anaesthetics |
• anestesia epidurale nelle 2 ore precedenti all’espletamento del parto; • parto operativo con applicazione di forcipe o ventosa; • patologia psichiatrica; • parto gemellare; • allergie note agli strumenti di studio; • precedenti reazioni avverse ad anestetici locali |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To evaluate the efficacy and safety of using a local anaesthetic spray, commonly used in clinical practice as an off label, during suturing of perineal lacerations in the postpartum period, comparing it with the standard technique involving infiltration of the lacerated tissues. |
Valutare l’efficacia e la sicurezza dell’utilizzo di un anestetico locale spray, utilizzato comunemente nella pratica clinica come off label, durante la sutura di lacerazioni perineali nel post-partum, confrontandola con la tecnica standard che prevede l’infiltrazione dei tessuti lacerati. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | 36 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 12 |
E.8.9.2 | In all countries concerned by the trial days | 36 |